Sandoz receives FDA nod for biosimilar Hyrimoz citrate-free HCF formulation
The formulation is approved to treat seven indications, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis and plaque psoriasis.